Incyte has announced promising results from the Phase 3 POD1UM-304 trial evaluating retifanlimab (Zynyz®), a PD-1-targeting monoclonal antibody, in combination with platinum-based chemotherapy for adults with previously untreated metastatic non-small cell lung cancer (NSCLC). The trial included patients with both…
AbbVie has unveiled key findings from its latest Emotional Impact Report (EIR), offering insights into the mental health challenges faced by patients with chronic lymphocytic leukemia (CLL). For the first time, the survey highlights the unique emotional experiences of Hispanic,…
Stoke Therapeutics has announced new data from its Phase 1/2a and open-label extension (OLE) studies on zorevunersen, a potential disease-modifying treatment for Dravet syndrome. The data revealed significant and lasting reductions in convulsive seizure frequency in patients who received zorevunersen…
Eisai and Biogen Inc. have announced that Mexico’s Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has approved LEQEMBI (lecanemab), a humanized monoclonal antibody, for the treatment of early Alzheimer’s disease (AD). This approval marks an important step in…
CVS Health Corporation has disclosed the Reference Yield and Total Consideration for its previously announced cash tender offer (the “Any and All Tender Offer”) targeting its 4.100% Senior Notes due 2025 (the “Any and All Notes”). This tender offer is…
GSK plc and Medicines for Malaria Venture (MMV) have announced a major milestone in the fight against malaria, as the World Health Organization (WHO) has awarded prequalification to tafenoquine. This is the first single-dose medicine for the prevention of relapse…
Teva Pharmaceutical Industries has announced encouraging results from its Phase 3 SPACE study, which evaluated the efficacy and safety of AJOVY (fremanezumab) for preventing episodic migraines in children and adolescents aged 6 to 17 years. The study demonstrated a statistically…
Novo Nordisk has announced that 13 abstracts from its research will be presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Diego, California, from December 7 to 10, 2024. Of these, three…
The World Health Organization (WHO) convened the 40th meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on November 6, 2024. The committee, composed of members, advisers, and representatives from affected countries, reviewed data on wild poliovirus…
The National Home Infusion Association (NHIA) and Melinta Therapeutics, LLC, a biopharmaceutical company specializing in innovative therapies for acute and life-threatening conditions, are excited to announce Melinta’s membership in NHIA’s Future of Infusion Advisory Council (FIAC). This strategic advisory group…
Stallergenes Greer, a leading biopharmaceutical company specializing in allergen immunotherapy (AIT), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the extension of the indication…
Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical-stage botanical pharmaceutical company specializing in the development of unique botanical pharmaceutical and cosmeceutical products, has announced its financial results for the fiscal year ending July 31, 2024, as…